3D-Image-Guided Multi-Catheter Interstitial Brachytherapy for Bulky and High-Risk Stage IIB–IVB Cervical Cancer
This study aimed to evaluate the efficacy and safety of computed tomography-magnetic resonance imaging (CT-MRI)-guided multi-catheter interstitial brachytherapy for patients with bulky (≥4 cm) and high-risk, stage IIB–IVB advanced cervical cancer. Eighteen patients who underwent concurrent chemoradi...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-02-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/5/1257 |
| _version_ | 1797475474008440832 |
|---|---|
| author | Tetsuya Kokabu Koji Masui Yosuke Tarumi Naoki Noguchi Kohei Aoyama Hisashi Kataoka Hiroshi Matsushima Kaori Yoriki Daisuke Shimizu Hideya Yamazaki Kei Yamada Taisuke Mori |
| author_facet | Tetsuya Kokabu Koji Masui Yosuke Tarumi Naoki Noguchi Kohei Aoyama Hisashi Kataoka Hiroshi Matsushima Kaori Yoriki Daisuke Shimizu Hideya Yamazaki Kei Yamada Taisuke Mori |
| author_sort | Tetsuya Kokabu |
| collection | DOAJ |
| description | This study aimed to evaluate the efficacy and safety of computed tomography-magnetic resonance imaging (CT-MRI)-guided multi-catheter interstitial brachytherapy for patients with bulky (≥4 cm) and high-risk, stage IIB–IVB advanced cervical cancer. Eighteen patients who underwent concurrent chemoradiotherapy with multi-catheter interstitial brachytherapy between September 2014 and August 2020 were enrolled. The prescribed dose of external beam radiotherapy was 45–50.4 Gy, and the brachytherapy high-dose-rate aim was 25–30 Gy per 5 fractions. The endpoints were four-year local and pelvic control rates, four-year disease-free and overall survival rates, and the adverse events rate. The median follow-up period was 48.4 months (9.1–87.5 months). Fifteen patients received concurrent cisplatin therapy (40 mg/m<sup>2</sup>, q1week). Four (22.2%), seven (38.9%), and seven (38.9%) patients had stage II, III, and IV cervical cancer, respectively. Pelvic and para-aortic lymph node metastases were observed in 11 (61.1%) and 2 (11.1%) patients, respectively. The median pre-treatment volume was 87.5 cm<sup>3</sup>. The four-year local control, pelvic control, disease-free survival, and overall survival rates were 100%, 100%, 81.6%, and 87.8%, respectively. Three (16.7%) patients experienced grade 3 adverse events, and none experienced grade 4–5 adverse events. CT-MRI-guided multi-catheter interstitial brachytherapy could be a promising treatment strategy for locally advanced cervical cancer. |
| first_indexed | 2024-03-09T20:44:38Z |
| format | Article |
| id | doaj.art-5671c5cae8804e03a372b4a5859cfe4f |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T20:44:38Z |
| publishDate | 2022-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-5671c5cae8804e03a372b4a5859cfe4f2023-11-23T22:48:14ZengMDPI AGCancers2072-66942022-02-01145125710.3390/cancers140512573D-Image-Guided Multi-Catheter Interstitial Brachytherapy for Bulky and High-Risk Stage IIB–IVB Cervical CancerTetsuya Kokabu0Koji Masui1Yosuke Tarumi2Naoki Noguchi3Kohei Aoyama4Hisashi Kataoka5Hiroshi Matsushima6Kaori Yoriki7Daisuke Shimizu8Hideya Yamazaki9Kei Yamada10Taisuke Mori11Department of Obstetrics and Gynecology, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto 602-8566, JapanDepartment of Radiology, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto 602-8566, JapanDepartment of Obstetrics and Gynecology, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto 602-8566, JapanDepartment of Radiology, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto 602-8566, JapanDepartment of Obstetrics and Gynecology, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto 602-8566, JapanDepartment of Obstetrics and Gynecology, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto 602-8566, JapanDepartment of Obstetrics and Gynecology, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto 602-8566, JapanDepartment of Obstetrics and Gynecology, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto 602-8566, JapanDepartment of Radiology, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto 602-8566, JapanDepartment of Radiology, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto 602-8566, JapanDepartment of Radiology, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto 602-8566, JapanDepartment of Obstetrics and Gynecology, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto 602-8566, JapanThis study aimed to evaluate the efficacy and safety of computed tomography-magnetic resonance imaging (CT-MRI)-guided multi-catheter interstitial brachytherapy for patients with bulky (≥4 cm) and high-risk, stage IIB–IVB advanced cervical cancer. Eighteen patients who underwent concurrent chemoradiotherapy with multi-catheter interstitial brachytherapy between September 2014 and August 2020 were enrolled. The prescribed dose of external beam radiotherapy was 45–50.4 Gy, and the brachytherapy high-dose-rate aim was 25–30 Gy per 5 fractions. The endpoints were four-year local and pelvic control rates, four-year disease-free and overall survival rates, and the adverse events rate. The median follow-up period was 48.4 months (9.1–87.5 months). Fifteen patients received concurrent cisplatin therapy (40 mg/m<sup>2</sup>, q1week). Four (22.2%), seven (38.9%), and seven (38.9%) patients had stage II, III, and IV cervical cancer, respectively. Pelvic and para-aortic lymph node metastases were observed in 11 (61.1%) and 2 (11.1%) patients, respectively. The median pre-treatment volume was 87.5 cm<sup>3</sup>. The four-year local control, pelvic control, disease-free survival, and overall survival rates were 100%, 100%, 81.6%, and 87.8%, respectively. Three (16.7%) patients experienced grade 3 adverse events, and none experienced grade 4–5 adverse events. CT-MRI-guided multi-catheter interstitial brachytherapy could be a promising treatment strategy for locally advanced cervical cancer.https://www.mdpi.com/2072-6694/14/5/1257cervical cancerinterstitial brachytherapyambulatory techniqueCTMRI |
| spellingShingle | Tetsuya Kokabu Koji Masui Yosuke Tarumi Naoki Noguchi Kohei Aoyama Hisashi Kataoka Hiroshi Matsushima Kaori Yoriki Daisuke Shimizu Hideya Yamazaki Kei Yamada Taisuke Mori 3D-Image-Guided Multi-Catheter Interstitial Brachytherapy for Bulky and High-Risk Stage IIB–IVB Cervical Cancer Cancers cervical cancer interstitial brachytherapy ambulatory technique CT MRI |
| title | 3D-Image-Guided Multi-Catheter Interstitial Brachytherapy for Bulky and High-Risk Stage IIB–IVB Cervical Cancer |
| title_full | 3D-Image-Guided Multi-Catheter Interstitial Brachytherapy for Bulky and High-Risk Stage IIB–IVB Cervical Cancer |
| title_fullStr | 3D-Image-Guided Multi-Catheter Interstitial Brachytherapy for Bulky and High-Risk Stage IIB–IVB Cervical Cancer |
| title_full_unstemmed | 3D-Image-Guided Multi-Catheter Interstitial Brachytherapy for Bulky and High-Risk Stage IIB–IVB Cervical Cancer |
| title_short | 3D-Image-Guided Multi-Catheter Interstitial Brachytherapy for Bulky and High-Risk Stage IIB–IVB Cervical Cancer |
| title_sort | 3d image guided multi catheter interstitial brachytherapy for bulky and high risk stage iib ivb cervical cancer |
| topic | cervical cancer interstitial brachytherapy ambulatory technique CT MRI |
| url | https://www.mdpi.com/2072-6694/14/5/1257 |
| work_keys_str_mv | AT tetsuyakokabu 3dimageguidedmulticatheterinterstitialbrachytherapyforbulkyandhighriskstageiibivbcervicalcancer AT kojimasui 3dimageguidedmulticatheterinterstitialbrachytherapyforbulkyandhighriskstageiibivbcervicalcancer AT yosuketarumi 3dimageguidedmulticatheterinterstitialbrachytherapyforbulkyandhighriskstageiibivbcervicalcancer AT naokinoguchi 3dimageguidedmulticatheterinterstitialbrachytherapyforbulkyandhighriskstageiibivbcervicalcancer AT koheiaoyama 3dimageguidedmulticatheterinterstitialbrachytherapyforbulkyandhighriskstageiibivbcervicalcancer AT hisashikataoka 3dimageguidedmulticatheterinterstitialbrachytherapyforbulkyandhighriskstageiibivbcervicalcancer AT hiroshimatsushima 3dimageguidedmulticatheterinterstitialbrachytherapyforbulkyandhighriskstageiibivbcervicalcancer AT kaoriyoriki 3dimageguidedmulticatheterinterstitialbrachytherapyforbulkyandhighriskstageiibivbcervicalcancer AT daisukeshimizu 3dimageguidedmulticatheterinterstitialbrachytherapyforbulkyandhighriskstageiibivbcervicalcancer AT hideyayamazaki 3dimageguidedmulticatheterinterstitialbrachytherapyforbulkyandhighriskstageiibivbcervicalcancer AT keiyamada 3dimageguidedmulticatheterinterstitialbrachytherapyforbulkyandhighriskstageiibivbcervicalcancer AT taisukemori 3dimageguidedmulticatheterinterstitialbrachytherapyforbulkyandhighriskstageiibivbcervicalcancer |